Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
87.62
+0.34 (+0.39%)
Streaming Delayed Price
Updated: 2:46 PM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...
Via
MarketMinute
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...
Via
Finterra
Topics
Economy
Intellectual Property
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...
Via
MarketMinute
Topics
Intellectual Property
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss
↗
February 26, 2026
Via
Chartmill
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March
↗
January 09, 2026
Via
Stocktwits
Is This Weight Loss Drug Stock a Buy After a New Approval?
↗
March 31, 2026
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
Via
The Motley Fool
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
↗
March 04, 2026
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
↗
March 04, 2026
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Rhythm Pharmaceuticals's Earnings: A Preview
↗
November 03, 2025
Via
Benzinga
Rhythm Pharma (RYTM) Earnings Call Transcript
↗
February 26, 2026
Rhythm Pharma (RYTM) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via
The Motley Fool
Topics
Regulatory Compliance
Prediction: These 3 Stocks Will Crush the Market in 2026
↗
February 16, 2026
These stocks all have catalysts on the way that could provide great news for investors.
Via
The Motley Fool
Topics
Artificial Intelligence
This High-Flying Growth Stock Is Hiding in Plain Sight
↗
February 02, 2026
This biotech stock is flying under the radar for many investors, but Wall Street loves it.
Via
The Motley Fool
The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
December 30, 2025
As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...
Via
MarketMinute
Topics
ETFs
Economy
World Trade
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder
↗
December 11, 2025
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.
Via
Stocktwits
The market is filled with gapping stocks in Thursday's session.
↗
December 11, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
Stay updated with the stocks that are on the move in today's after-hours session.
↗
December 10, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
These stocks are moving in today's after hours session
↗
November 11, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
↗
November 08, 2025
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
Via
The Motley Fool
Topics
Regulatory Compliance
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results
↗
November 04, 2025
Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.
Via
Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
October 27, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
2 Under-the-Radar Stocks That Could Soar
↗
September 21, 2025
They could ride the wave of the hottest therapeutic area in the industry.
Via
The Motley Fool
Peering Into Rhythm Pharmaceuticals's Recent Short Interest
↗
September 11, 2025
Via
Benzinga
12 Analysts Have This To Say About Rhythm Pharmaceuticals
↗
August 06, 2025
Via
Benzinga
Rhythm (RYTM) Q2 Revenue Jumps 67%
↗
August 05, 2025
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
